期刊文献+

厄贝沙坦氢氯噻嗪治疗原发性高血压疗效观察 被引量:1

Irbesartan Hydrochlorothiazide Clinical Efficacy of Treatment of Essential Hypertension
下载PDF
导出
摘要 目的:观察厄贝沙坦氢氯噻嗪治疗的临床疗效。方法:选择130例原发性高血压患者,随机分对照组和治疗组各65例。治疗组用厄贝沙坦氢氯噻嗪片治疗,对照组应单用厄贝沙坦治疗。疗程均为8周。8周过后,分别观察这2组4周和8周的治疗效果。结果:治疗组和对照组的总有效率分别是90.7%和75.4%。2组总有效率比较,差异有统计学意义(P<0.05)。结论:厄贝沙坦氢氯噻嗪片治疗原发性高血压效果显著,优于厄贝沙坦治疗,值得临床借鉴。 Objection:Investigate the irbesartan and hydrochlorothiazide tablets in treating patients. Methods: Divided 130 patients of primary hypertension into two groups. The treatment group with 65cases, and the control group 65 patients. The treatment group were treated with irbesartan hydrochlorothiazide tablets and control group were treated with irbesartan. All patients were observed continuously for 8 weeks. 8 weeks later, and observed effects after 4 weeks and 8 weeks. Results:The effective rate of treatment group was 90.75%, and that of the control group was75.4%. Difference of efficiency between the two groups was statistically significant( P 〈 0. 05). Conclusion: The effect of Irbesartan Hydrochlorothiazide tablets were significantly superior to irbesartan. Essential hypertension
作者 何丽冰
出处 《中国伤残医学》 2013年第7期51-52,共2页 Chinese Journal of Trauma and Disability Medicine
关键词 厄贝沙坦氢氯噻嗪 厄贝沙坦 高血压 Irbesartan Hydrochlorothiazide Irbesartan Hypertension
  • 相关文献

参考文献1

二级参考文献24

  • 1[10]NAKASHIMA M, UMEMURA K. The clinical pharmacology of losartan in Japanese subjects and patients[J]. Blood Press Suppl,1996,2:62-66.
  • 2[11]SONG JC, WHITE CM. Pharmacologic, pharmacokinetic, and therapeutics differences among angiotensin Ⅱreceptor antagonists [J]. Pharmacotherapy, 2000,20(2):130-139.
  • 3[12]NEUTEL JM, KLEIN C, MEINICKE TW, et al. Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications[J].Blood Press,2002,11(5):302-309.
  • 4[13]PRASAD PP, YEH CM, GURRIERI P, et al. Pharmacokinetics of multiple doses of valsartan in patients with heart failure[J]. J Cardiovasc Pharmacol,2002,40(5):801-807.
  • 5[14]SMITH DH, MATZEK KM, KEMPTHORNE-RAWSOWL J. Dose response and safety of telmisartan in patients with mild to moderate hypertension[J]. J Clin Pharmacol,2000,40(12 Pt 1):1380-1390.
  • 6[15]SASAKI M, FUJIMURA A, HARADA K, et al. Clinical pharmacology of multiple-dose losartan an angiotensin Ⅱ receptor antagonist, in patients with essential hypertension[J]. J Clin Pharmacol, 1996, 36(5):403-408.
  • 7[16]RUILOPE L. Human pharmacokinetic/pharmacodynemic profile of irbesartan: a new potent angiotensin Ⅱ receptor antagonist[J]. J Hypertens Suppl,1997 ,15 (7):S15-S20.
  • 8[17]McCLELLAN KJ, GOA KL. Candesartan cilexetil. A review of its use in essential hypertension[J]. Drugs,1998,56(5):847-869.
  • 9[18]PHILIPP T, LETZEL H, ARENS HJ. Dose-finding study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate hypertension[J]. J Hum Hypertens,1997 ,11 Suppl 2:S67-S68.
  • 10[19]McGILL JB, REILLY PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized ,double-blind, placebo-controlled, parallel-group trial [J]. Clin Ther,2001, 23(6):833-850.

共引文献35

同被引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部